Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | KLK7 | P49862 | 2/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.47 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | PREP | P48147 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28003378 | 1.00 | PARP1 (0.53) | PARP1KLK7PDE4BPDK1PDK2 | |
| SCHEMBL3782792 | 0.96 | KLK7 (0.50) | PARP1KLK7PDE4BPDK1PDK2 | |
| SCHEMBL15606326 | 0.89 | PARP1 (0.57) | PARP1KLK7PDK1PDK2PDK3 | |
| SCHEMBL30289174 | 0.89 | PARP1 (0.57) | PARP1KLK7PDK1PDK2PDK3 | |
| SCHEMBL20129643 | 0.87 | PARP1 (0.55) | PARP1KLK7PDE4BPDK1PDK2 | |
| SCHEMBL13681760 | 0.87 | PARP1 (0.55) | PARP1KLK7PDE4BPDK1PDK2 | |
| SCHEMBL2820733 | 0.87 | PARP1 (0.55) | PARP1KLK7PDE4BPDK1PDK2 | |
| SCHEMBL6335353 | 0.86 | PARP1 (0.54) | PARP1KLK7PDK1PDK2PDK3 | |
| SCHEMBL17153137 | 0.85 | PARP1 (0.53) | PARP1KLK7PDK1PDK2PDK3 | |
| SCHEMBL21528001 | 0.85 | PDK1 (0.55) | PARP1KLK7PDK1PDK2PDK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170157118-A1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS | MACROPHAGE PHARMA LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
| US-20170157118-A1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS | MACROPHAGE PHARMA LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
| US-9604940-B2 | 2-aminopyrazine derivatives as CSF-1R kinase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2017-03-28 | — | — | US | disclosed |
| US-9604940-B2 | 2-aminopyrazine derivatives as CSF-1R kinase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2017-03-28 | — | — | US | disclosed |
| US-20150368210-A1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2015-12-24 | — | — | US | disclosed |
| US-20150368210-A1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2015-12-24 | — | — | US | disclosed |
| CN-104583199-A | 2-aminopyrazine derivatives as CSF-1R kinase inhibitors | CHROMA THERAPEUTICS LTD | 2015-04-29 | — | — | CN | disclosed |
| US-20140010762-A1 | IMAGING AGENTS | CHROMA THERAPEUTICS LTD (GB) | 2014-01-09 | — | — | US | disclosed |
| US-20140010762-A1 | IMAGING AGENTS | CHROMA THERAPEUTICS LTD (GB) | 2014-01-09 | — | — | US | disclosed |
| WO-2014001802-A1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2014-01-03 | — | — | WO | disclosed |
| WO-2012080705-A1 | IMAGING AGENTS | CHROMA THERAPEUTICS LTD (GB) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157118-A1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS | CSF1R, CSF3R, FLT3 | PARP1 1962/4885KLK7 1728/4885PDE4B 2876/4885 |
| US-20140010762-A1 | IMAGING AGENTS | CES1, CES2, NCEH1 | PARP1 3134/4885KLK7 3149/4885PDE4B 3245/4885 |
| US-20150368210-A1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS | CSF1R, CSF3R, FLT3 | PARP1 1962/4885KLK7 1728/4885PDE4B 2876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.